BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26595446)

  • 1. Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
    Kai AC; Richards T; Coleman A; Mallipeddi R; Barlow R; Craythorne EE
    Br J Dermatol; 2016 Jan; 174(1):165-8. PubMed ID: 26595446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
    Powell AM; Robson AM; Russell-Jones R; Barlow RJ
    Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
    Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
    Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
    Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod.
    Alarcon I; Carrera C; Alos L; Palou J; Malvehy J; Puig S
    J Am Acad Dermatol; 2014 Jul; 71(1):49-55. PubMed ID: 24725478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of lentigo maligna with imiquimod 5% cream.
    Hopson B; Richey D; Sajben FP
    J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.
    Spenny ML; Walford J; Werchniak AE; Beltrani V; Brennick JB; Storm CA; Perry AE; Chapman MS
    Cutis; 2007 Feb; 79(2):149-52. PubMed ID: 17388218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.
    Van Meurs T; Van Doorn R; Kirtschig G
    Dermatol Surg; 2010 Jun; 36(6):853-8. PubMed ID: 20618370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of lentigo maligna with imiquimod before staged excision.
    Cotter MA; McKenna JK; Bowen GM
    Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lentigo maligna treated with 5% imiquimod cream].
    Martín T; Ojeda A; Martínez S; Vera A
    Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imiquimod in the treatment of lentigo maligna.
    Rajpar SF; Marsden JR
    Br J Dermatol; 2006 Oct; 155(4):653-6. PubMed ID: 16965411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod therapy for lentigo maligna.
    Mahoney MH; Joseph MG; Temple C
    Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission of extensive lentigo maligna after treatment with imiquimod.
    Piazza CD; Sampaio SA
    An Bras Dermatol; 2009; 84(1):82-4. PubMed ID: 19377765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance].
    Lorentzen HF; Weismann K
    Ugeskr Laeger; 2005 Sep; 167(39):3696-7. PubMed ID: 16219219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
    Woodmansee CS; McCall MW
    Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
    [No Abstract]   [Full Text] [Related]  

  • 17. Topical imiquimod immunotherapy in the management of lentigo maligna.
    Powell AM; Russell-Jones R; Barlow RJ
    Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients.
    Ly L; Kelly JW; O'Keefe R; Sutton T; Dowling JP; Swain S; Byrne M; Curr N; Wolfe R; Chamberlain A; Haskett M
    Arch Dermatol; 2011 Oct; 147(10):1191-5. PubMed ID: 22006136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
    Swetter SM; Chen FW; Kim DD; Egbert BM
    J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.